Controlled and extended drug release behavior of chitosan-based nanoparticle carrier

Yuan, Quan; Shah, J.S.; Hein, San; Misra, R.D.K.

doi:10.1016/j.actbio.2009.08.027

Cited by 272 publications

(91 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meanwhile, chitosan can also be modified to achieve the sustained/ controlled release. Chitosan-alumino-silicate nanoparticles prepared by Yuan et al 34 had significant sustained/controlledrelease effects. pH of the environment and chitosan:aluminosilicate ratio also influence drug release.…”

Section: Characteristics Of Sustained/controlled Releasementioning

confidence: 99%

Recent advances of chitosan nanoparticles as drug carriers

Zeng¹

2011

IJN

253

124

View full text Add to dashboard Cite

Chitosan nanoparticles are good drug carriers because of their good biocompatibility and biodegradability, and can be readily modified. As a new drug delivery system, they have attracted increasing attention for their wide applications in, for example, loading protein drugs, gene drugs, and anticancer chemical drugs, and via various routes of administration including oral, nasal, intravenous, and ocular. This paper reviews published research on chitosan nanoparticles, including its preparation methods, characteristics, modification, in vivo metabolic processes, and applications.

show abstract

Section: Characteristics Of Sustained/controlled Releasementioning

confidence: 99%

Recent advances of chitosan nanoparticles as drug carriers

Zeng¹

2011

IJN

253

124

View full text Add to dashboard Cite

show abstract

“…Yuan et al also showed that DOX release from clay was much slower than from a chitosan/clay composite carrier. 23 When the drug was loaded to a chitosan/clay nanocomposite prior to the composite preparation as in Group D scaffolds, no competitive intercalation and exfoliation of the clay was expected. Therefore, the drug-release rate was faster as a low affinity of DOX to clay was anticipated.…”

Section: +mentioning

confidence: 99%

“…19,20 Chitosan/clay nanocomposites are also potential sustained drug-release carriers. [21][22][23] Both chitosan and calcium phosphate compounds, eg, hydroxyapatite or β-tricalcium phosphate, are widely used in bone tissue engineering because of their osteogenic properties. In addition, studies have shown that incorporation of clay with chitosan and hydroxyapaptite improves both mechanical and osteogenic scaffold properties.…”

Section: Introductionmentioning

confidence: 99%

Fabrication and characterization of a rapid prototyped tissue engineering scaffold with embedded multicomponent matrix for controlled drug release

Chen

Le²,

Hein

et al. 2012

IJN

View full text Add to dashboard Cite

Abstract:Bone tissue engineering implants with sustained local drug delivery provide an opportunity for better postoperative care for bone tumor patients because these implants offer sustained drug release at the tumor site and reduce systemic side effects. A rapid prototyped macroporous polycaprolactone scaffold was embedded with a porous matrix composed of chitosan, nanoclay, and β-tricalcium phosphate by freeze-drying. This composite scaffold was evaluated on its ability to deliver an anthracycline antibiotic and to promote formation of mineralized matrix in vitro. Scanning electronic microscopy, confocal imaging, and DNA quantification confirmed that immortalized human bone marrow-derived mesenchymal stem cells (hMSC-TERT) cultured in the scaffold showed high cell viability and growth, and good cell infiltration to the pores of the scaffold. Alkaline phosphatase activity and osteocalcin staining showed that the scaffold was osteoinductive. The drug-release kinetics was investigated by loading doxorubicin into the scaffold. The scaffolds comprising nanoclay released up to 45% of the drug for up to 2 months, while the scaffold without nanoclay released 95% of the drug within 4 days. Therefore, this scaffold can fulfill the requirements for both bone tissue engineering and local sustained release of an anticancer drug in vitro. These results suggest that the scaffold can be used clinically in reconstructive surgery after bone tumor resection. Moreover, by changing the composition and amount of individual components, the scaffold can find application in other tissue engineering areas that need local sustained release of drug.

show abstract

“…13,15 Among the numerous biological nanomaterials available, chitosan-based nanoparticles are one of the best studied drug delivery systems and have been widely used to load drugs due to the biodegradability and biocompatibility of chitosan. [16][17][18] However, chitosan cannot be dissolved in solution with a pH 6.5, which limits its application in vivo, especially as a cytokine delivery system, given that the bioactivity of cytokines require a physiological pH of 7. 35-7.45.…”

mentioning

confidence: 99%

Novel stable cytokine delivery system in physiological pH solution: chitosan oligosaccharide/heparin nanoparticles

Wang

Tan

Deng

et al. 2015

IJN

View full text Add to dashboard Cite

Background Cell therapy is a promising strategy for tissue regeneration. Key to this strategy is mobilization and recruitment of exogenous or autologous stem/progenitor cells by cytokines. However, there is no effective cytokine delivery system available for clinic application, in particular for myocardial regeneration. The aim of this study was to develop a novel cytokine delivery system that is stable in solution at physiological pH. Methods Four groups of self-assembled chitosan oligosaccharide/heparin (CSO/H) nanoparticles were prepared with various volume ratios of chitosan oligosaccharide to heparin (5:2, 5:4, 4:15, 1:5) and characterized by laser diffraction, particle size analysis, and transmission electron microscopy. The encapsulation efficiency and loading content of two cytokines, ie, stromal cell-derived factor (SDF)-1α and vascular endothelial growth factor (VEGF) were quantified using an enzyme-linked immunosorbent assay. The biological activity of the loaded SDF-1α and VEGF was evaluated using the transwell migration assay and MTT assay. The dispersion profiles for the cytokine-loaded nanoparticles were quantified using fluorescence molecular tomography. Results CSO/H nanoparticles were prepared successfully in solution with physiological pH. The particle sizes in the four treatment groups were in the range of 96.2–210.5 nm and the zeta potential ranged from −29.4 mV to 24.2 mV. The loading efficiency in the CSO/H nanoparticle groups with the first three ratios was more than 90%. SDF-1α loaded into CSO/H nanoparticles retained its migration activity and VEGF loaded into CSO/H nanoparticles continued to show proliferation activity. The in vivo dispersion test showed that the CSO/H nanoparticles enabled to VEGF to accumulate locally for a longer period of time. Conclusion CSO/H nanoparticles have a high cytokine loading capacity and allow cytokines to maintain their bioactivity for longer, are stable in an environment with physiological pH, and may be a promising cytokine delivery system for tissue regeneration.

show abstract

Controlled and extended drug release behavior of chitosan-based nanoparticle carrier

Cited by 272 publications

References 22 publications

Recent advances of chitosan nanoparticles as drug carriers

Recent advances of chitosan nanoparticles as drug carriers

Fabrication and characterization of a rapid prototyped tissue engineering scaffold with embedded multicomponent matrix for controlled drug release

Novel stable cytokine delivery system in physiological pH solution: chitosan oligosaccharide/heparin nanoparticles

Contact Info

Product

Resources

About

Controlled and extended drug release behavior of chitosan-based nanoparticle carrier

Cited by 272 publications

References 22 publications

Recent advances of chitosan nanoparticles as drug carriers

Recent advances of chitosan nanoparticles as drug carriers

Fabrication and characterization of a rapid prototyped tissue engineering scaffold with embedded multicomponent matrix for controlled drug release

Novel stable cytokine delivery system&nbsp;in physiological pH solution: chitosan oligosaccharide/heparin nanoparticles

Contact Info

Product

Resources

About

Novel stable cytokine delivery system in physiological pH solution: chitosan oligosaccharide/heparin nanoparticles